Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108827 | 0.90 | KCNA3 (0.48) | KCNA3OPRD1HSD11B1ADRA1AOPRM1 | |
| SCHEMBL1108894 | 0.88 | HSD11B1 (0.40) | OPRD1HSD11B1ADRA1AOPRM1OPRK1 | |
| SCHEMBL1108895 | 0.86 | OPRD1 (0.39) | OPRD1HSD11B1ADRA1AOPRM1OPRK1 | |
| SCHEMBL1108830 | 0.82 | SMN1; SMN2 (0.44) | MEN1KMT2AOPRD1OPRM1OPRK1 | |
| SCHEMBL1108884 | 0.82 | OPRD1 (0.43) | OPRD1HSD11B1OPRM1OPRK1NR1I2 | |
| SCHEMBL1108883 | 0.81 | HSD11B1 (0.44) | OPRD1HSD11B1OPRM1OPRK1KCNH2 | |
| SCHEMBL1108828 | 0.81 | AKR1C1 (0.44) | MEN1KMT2AKCNA3OPRD1HSD11B1 | |
| SCHEMBL1108852 | 0.80 | OPRD1 (0.47) | KMT2AOPRD1HSD11B1OPRK1NR1I2 | |
| SCHEMBL1108867 | 0.80 | OPRM1 (0.49) | OPRD1HSD11B1OPRM1OPRK1NR1I2 | |
| SCHEMBL1108865 | 0.79 | OPRL1 (0.46) | OPRD1HSD11B1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | HSD11B1, HSD17B1, HSD17B3 | MEN1 2815/4885KMT2A 3174/4885KCNA3 3296/4885 |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | GPR119, CYP11B2, CYP11B1 | MEN1 2451/4885KMT2A 3005/4885KCNA3 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.